Alector snags $32 mln Series C

Alector, a biotech company that focuses on treating Alzheimer’s disease and other neurodegenerative disorders, has secured $32 million in Series C financing. The investors included OrbiMed, Polaris Partners, Google Ventures, Topspin Partners and Mission Bay Capital.

Next Frontier Capital, Sears Capital, Z Investments and others back SiteOne

Bozeman, Montana-based SiteOne Therapeutics, a developer of new drugs, has secured an undisclosed amount of funding. The investors included Next Frontier Capital, 2M Companies Inc, Sears Capital Management, Biobrit LLC, Mission Bay Capital and Z Investments. In addition to the funding, Will Price, founder and managing partner of Next Frontier Capital, has been added to SiteOne’s board of directors.


Mission Bay Fund II raises $25 mln

Mission Bay Capital LLC said Monday it closed its second fund at $25 million. Fund II investors include several institutions and private individuals, including Jack Wadsworth, honorary chairman at Morgan Stanley Asia; Brook Byers, partner at venture capital firm Kleiner Perkins Caufield & Byers; the UCSF Foundation; the William K. Bowes, Jr. Foundation; Sobrato Capital; Capital Pacific; Novozymes; Chote Sophonpanich; Michael F. Koehn; and Leslie and Mac McQuown. Mission Bay Capital invests in life science companies emerging from the University of California and the San Francisco Bay Area.

Symic Biomedical snags $15 mln Series A

San Francisco-based Symic Biomedical, a healthcare-focused biotech firm, has raised $15 million in Series A funding. Lilly Ventures led the round with participation from other investors that included Den Danske Forskningsfond, Mitsui Global Investment, Ally Bridge Group, InCube Ventures, Purdue Foundry Investment Fund, Mission Bay Capital and QB3 Partners. In addition to the funding, Symic Biomedical has appointed Dr. Armen Shanafelt, a general partner at Lilly Ventures and Dr. Claus Christiansen, chairman of Nordic Biosciences, to its board of directors.


Mission Bay Capital backs Circle Pharma

San Francisco-based early-stage biotech firm Circle Pharma said Monday that it has secured an undisclosed amount of seed funding. The investors were Pfizer and QB3’s seed-stage venture fund Mission Bay Capital.


Life Science Angels leads a $1.5 mln seed round in Zephyrus Biosciences

Life Science Angels has led a $1.5 million seed funding in biotech company Zephyrus Biosciences. Other investors in the seed round include Mission Bay Capital, The Angel Forum and the Stanford StartX Fund, as well as individual investors in the life science community. Zephyrus also raised $350,000 in a grant from the National Institute of Health and $10,000 from the U.C. Bakar Fellows Program.

Principia Biopharma nabs $50 mln Series B funds

Principia Biopharma has raised $50 million in Series B financing. Sofinnova Ventures led the round with participation from investors that include Morgenthaler Ventures, New Leaf Venture Partners, OrbiMed, SR One and Mission Bay Capital. In addition to the financing, Dr. Srinivas Akkaraju, a general partner at Sofinnova Ventures, has been added to Principia Biopharma’s board of directors. Based in South San Francisco, Principia Biopharma is focused on developing small molecule drugs within the fields of autoimmune disease and oncology.

eFFECTOR Therapeutics Raises $45 Million Series A

Biopharmaceutical company eFFECTOR Therapeutics has completed a $45 million Series A financing. Investors include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital.

Principia Biopharma Inks $12.5M

Principia Biopharma Inc., a biopharmaceutical company focused on immunology, autoimmune diseases, and oncology, has raised $12.5 million. Investors include New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.

Mission Bay Capital Fund Launches

The California Institute of Quantitative Biosciences has formed a $7.5 million VC funding to provide startup capital for UC bioscience entrepreneurs and a long-term endowment for Qb3. It is being called the Mission Bay Capital Fund.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget